Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

NCT05415137 is registered in ClinicalTrials.gov with aTyr Pharma, Inc. as lead sponsor.

NCT NCT05415137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05415137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
Lead sponsor
aTyr Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 15, 2022
Completion date
July 14, 2025
Enrollment
268 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary sarcoidosis